Physician profile
Nancy A Squires
NPI 1841299906
$4,823.72
in general payments reported to CMS, 2019-2025
24 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,107 · 2020: $634 · 2021: $961 · 2022: $577 · 2023: $323 · 2024: $893 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,525 · Consulting Fee: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.76 |
| Consulting Fee | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,606.25 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $505.35 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $360.23 | 2019-2024 | Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.03 | 2019-2024 | Jardiance |
| Amgen INC. | $280.11 | 2019-2022 | |
| Astellas Pharma US INC | $275.17 | 2019-2021 | |
| Lilly USA, LLC | $237.99 | 2019-2024 | Zepbound, Mounjaro |
| Roche Molecular Systems, INC. | $200.00 | 2022 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Organogenesis INC. | $118.40 | 2021 | |
| Merck Sharp & Dohme LLC | $91.27 | 2019-2021 | |
| Smith+Nephew, INC. | $89.60 | 2019 | |
| Pfizer INC. | $70.21 | 2021 | |
| Novartis Pharmaceuticals Corporation | $69.79 | 2019-2020 | |
| Amarin Pharma, INC. | $64.47 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $62.53 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $59.40 | 2021 | |
| Abbvie INC. | $52.98 | 2022-2024 | Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $52.31 | 2022-2024 | |
| Allergan, INC. | $44.41 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $39.60 | 2020 | |
| Janssen Pharmaceuticals, INC | $35.91 | 2019 | |
| Dexcom, INC. | $24.83 | 2023 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $17.88 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Squires listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.